Examples of 'nateglinide' in a sentence
Meaning of "nateglinide"
nateglinide (adjective): This term is an adjective used to describe a medication or substance that is related to or containing nateglinide, which is a drug used to treat type 2 diabetes by stimulating insulin release
Show more definitions
- A meglitinide drug for the treatment of type II diabetes that lowers blood glucose by stimulating the release of insulin from the pancreas.
How to use "nateglinide" in a sentence
Basic
Advanced
nateglinide
The single use of nateglinide is especially preferable.
An example of a prandial glucose regulator is repaglinide or nateglinide.
Nateglinide should not be used in monotherapy.
The operation can be conducted by nateglinide alone.
Nateglinide and its metabolites are rapidly and completely eliminated.
The meglitinide can be nateglinide or repaglinide.
Trazec is a medicine contains the active substance nateglinide.
Nateglinide was not teratogenic in rats.
Age did not influence the pharmacokinetic properties of nateglinide.
Nateglinide is extensively metabolised.
Starlix is a medicine containing the active substance nateglinide.
Nateglinide is excreted in the milk following a peroral dose to lactating rats.
The active substance is nateglinide.
Nateglinide should be used with caution in patients with moderate hepatic impairment.
A hydrophilic material is preferable as a carrier that makes nateglinide amorphous.
See also
Nateglinide has shown a low potential for protein displacement in in vitro studies.
Other methods are also acceptable if only it can make nateglinide amorphous.
No clinically significant differences in nateglinide pharmacokinetics were observed between men and women.
Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas.
The pharmacodynamics of repaglinide and nateglinide was assessed by measuring blood glucose concentrations.
Data available from both in vitro and in vivo experiments indicate that nateglinide is predominantly.
The preparation containing amorphous nateglinide of the present invention comprises a hydrophilic material.
Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.
The preparation containing amorphous nateglinide of the present invention can further comprise hydrophilic materials.
Nateglinide is metabolized by the mixed-function oxidase system prior to elimination.
O Mirtazapine et ses seis Nateglinide and its salts and derivatives.
C nateglinide is recovered in the urine within six hours post-dose.
Product name Nateglinide.
The dissolution rate of nateglinide was controlled in comparison with the immediate release granules.
In some embodiments, the meglitinide is nateglinide or repaglinide.
It indicates that amorphous nateglinide tablets are the preparation having high conservation stability.
Conversely, these medicinal products had no effect on the pharmacokinetics of nateglinide.
Specific patient groups Nateglinide should be used with caution in patients with moderate hepatic impairment.
In one embodiment, meglitinides include but are not limited to prandin or nateglinide.
Meanwhile, nateglinide has crystal polymorphs.
More specifically, it relates to industrially beneficial methods for crystallization of nateglinide.
However, nateglinide was then rapidly released.
Furthermore, the present compounds may be administered in combination with nateglinide.
Like other insulin secretagogues, nateglinide is capable of producing hypoglycaemia.
However, it can not be regarded as effective in all crystal forms of nateglinide.
A method for producing nateglinide crystals comprising the steps of,.
Examples of meglitinides include, but are not limited to nateglinide and repaglinide.
With these, nateglinide can be formed into a controlled release preparation.
Among the non-sulphonylurea insulin secretagogues, repaglinide and nateglinide are preferred.
The dosage of nateglinide should be determined by the physician according to the patient 's.
Examples of such non-sulfonylurea insulin secretagogues include nateglinide and repaglinide.
The dosage of nateglinide should be determined by the physician according to the patient ' s requirements.
Two analogues are currently available for clinical use, repaglinide and nateglinide.
Examples of meglitinides include repaglinide, nateglinide and other meglitinides known in the art.
In another embodiment, a compound of the present invention may be administered in combination with nateglinide.
